Navigation Links
Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA
Date:4/28/2008

EVANSTON, Ill., April 28 /PRNewswire-FirstCall/ -- Northfield Laboratories Inc. (Nasdaq: NFLD). Northfield Laboratories Inc. issued the following statement in response to a May 21 publication in the Journal of the American Medical Association entitled Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis and the accompanying editorial released online today.

"Meta-analyses that compare varied products under the umbrella of an entire class are a useful tool to raise questions that may merit answers with respect to the class," said Steven A. Gould, M.D., Chairman and Chief Executive Officer of Northfield Laboratories, Inc. "But it is important to note what meta-analyses cannot accomplish. Meta-analysis is not designed to provide answers about specific products or to examine fully the risk/benefit ratio of any particular product. Rather, that is the role of clinical trials that are focused on a particular product and are conducted to assess its safety and efficacy in relation to a proposed indication. Northfield will present such data on its product, PolyHeme(R) next week at the FDA/NIH-sponsored workshop on Hemoglobin Based Oxygen Carriers (HBOCs.)"

The workshop, sponsored jointly by the Food and Drug Administration and the National Institutes of Health, will be held on April 28 and 29 in Bethesda, Maryland. It will examine the current status and future directions of HBOCs. Steven A. Gould, M.D., will present a talk on the clinical development of PolyHeme(R), Northfield Laboratories' investigational red cell substitute. His talk will include a summary of the clinical studies conducted by the Company and reported to the FDA.

About the Workshop

The two-day public workshop, Hemoglobin-Based Oxygen Carriers: Current Status and Future Directions, is sponsored by the Food and Drug Administration, the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Department of Health and Human Services' Office of the Secretary and Office of Public Health and Science (OS/OPHS). The purpose of the workshop is to gather the available scientific information and hear informed opinion on the safety of HBOCs in relation to a variety of clinical use settings as a basis to advance the field.

About Northfield Laboratories and PolyHeme(R)

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. Northfield's product, PolyHeme(R), is under clinical investigation as oxygen-carrying red blood cell substitute. It is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit http://www.northfieldlabs.com.

FOR FURTHER INFORMATION CONTACT:

Sophia H. Twaddell

Vice President, Corporate Communications

(847) 864-3500

stwaddell@northfieldlabs.com


'/>"/>
SOURCE Northfield Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Northfield Automation Announces Wholly Owned Subsidiary to Diversify Into Medical Device Market
2. NIOXIN(R) Research Laboratories First to Market HairDX Genetic Test for Womens Hair Loss
3. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
4. IDEXX Laboratories to Release 2008 First Quarter Financial Results
5. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
6. Breckenridge Pharmaceutical Signs Letter of Intent for Long Term Agreement With Orit Laboratories (West Caldwell, NJ)
7. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings
8. Stiefel Laboratories Appoints First Chief Scientific Officer
9. Underwriters Laboratories Management System Registration Business to Merge With Germanys DQS
10. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
11. Bond Laboratories First Quarter Fiscal 2008 Sales Exceeding Internal Projections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... SuperCloset is proud to officially launch our ... to day issues, struggles and obstacles veterans’ need to overcome in order to face ... active or retired military veteran(s) with a donated SuperCloset product based on the needs ...
(Date:5/28/2016)... ... ... After a year and a half of planning the Multiple Pathways of Recovery Conference ... of Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel ... to explore the many pathways individuals use to get into and sustain their recovery. ...
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... caregivers to casual readers, this installment is bolstered by inspiring human-interest stories, courtesy ... trends and tech within the industry, from leading advocates, associations and industry leaders ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 ARANZ Medical  Ltd ... healthcare sector, has been named the Coretex Hi-Tech Emerging Company ... Dr Bruce Davey , CEO of ARANZ ...  It,s really good to be recognised for the work we ... are used in 35 countries around the world from Sub-Saharan ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... KONG , May 24, 2016 ... , the world , s first ... AV fistula intervention   OrbusNeich, a global ... has expanded its portfolio to include products to treat ... are the company,s first entry devices for lower limb ...
Breaking Medicine Technology: